NCT06379893View on ClinicalTrials.gov

A Real-World Evidence Study to Evaluate the Effects of Voltaren Use on Mobility and Quality of Life in Participants With Knee Osteoarthritis Pain

PHASE4CompletedINTERVENTIONAL
Enrollment

196

Participants

Timeline

Start Date

April 25, 2024

Primary Completion Date

October 29, 2024

Study Completion Date

October 29, 2024

Conditions
Pain
Interventions
DRUG

Voltaren Gel 1% (diclofenac sodium) (US only)

Participants in the US will use Volatren Gel containing 1% diclofenac sodium.

DRUG

Voltaren Gel 1.16% (diclofenac diethylammonium) (EU only)

Participants in the EU will use Volatren Gel containing 1.16% diclofenac diethylammonium.

DRUG

Voltaren Gel 2.32% (diclofenac diethylammonium) (EU only)

Participants in the EU will use Volatren Gel containing 2.32% diclofenac diethylammonium.

Trial Locations (8)

70072

Tandem Clinical Research, Marrero

78209

Quality Research Inc, San Antonio

85-079

Vitamed Gałaj I Cichomski sp.j., Bydgoszcz

89-600

Centrum Medyczne Lukamed., Chojnice

40-282

Silmedic sp. z o.o., Katowice

90-302

Santa Sp. z o.o. Santa Familia PTG Lodz, Lodz

82-200

Centrum Badawcze Panaceum Agnieszka Brzezicka, Magdalena Lenkiewicz Sp z .o.o, Malbork

14-100

Specjalistyczny Osrodek Lecziczo Badawczy (SOLB) Zbgniew Żęgota, Ostróda

All Listed Sponsors
lead

HALEON

INDUSTRY

NCT06379893 - A Real-World Evidence Study to Evaluate the Effects of Voltaren Use on Mobility and Quality of Life in Participants With Knee Osteoarthritis Pain | Biotech Hunter | Biotech Hunter